D
Donald Rao
Researcher at Baylor College of Medicine
Publications - 34
Citations - 1368
Donald Rao is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Small hairpin RNA & RNA interference. The author has an hindex of 14, co-authored 34 publications receiving 1210 citations. Previous affiliations of Donald Rao include Texas Oncology.
Papers
More filters
Journal ArticleDOI
siRNA vs. shRNA: similarities and differences.
TL;DR: This review will compare siRNA, shRNA and bi-functional shRNA, finding that optimized shRNA constructs allow for high potency and sustainable effects using low copy numbers resulting in less off-target effects, particularly if embedded in a miRNA scaffold.
Journal ArticleDOI
Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
Neil Senzer,Minal A. Barve,Joseph A. Kuhn,Anton Melnyk,Peter Beitsch,Martin Lazar,Samuel Lifshitz,Mitchell Magee,Jonathan Oh,Susan W Mill,Cynthia Bedell,Candice Higgs,Padmasini Kumar,Yang Yu,Fabienne Norvell,Connor Phalon,Nicolas Taquet,Donald Rao,Zhaohui Wang,Chris M. Jay,Beena O. Pappen,Gladice Wallraven,F. Charles Brunicardi,David M. Shanahan,Phillip B. Maples,John Nemunaitis +25 more
TL;DR: In conclusion, FANG vaccine was safe and elicited an immune response correlating with prolonged survival, and Phase II assessment is justified.
Journal ArticleDOI
RNA interference and cancer therapy.
TL;DR: The potential for, challenges to, and the current status of RNAi-based cancer therapeutics are discussed.
Journal ArticleDOI
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Maurizio Ghisoli,Maurizio Ghisoli,Minal A. Barve,Robert G. Mennel,Robert G. Mennel,Carl Lenarsky,Carl Lenarsky,Staci Horvath,Gladice Wallraven,Beena O. Pappen,Samuel H. Whiting,Donald Rao,Neil Senzer,John Nemunaitis +13 more
TL;DR: Long-term follow-up results show a survival benefit without evidence of significant toxicity to Vigil when administered once monthly by intradermal injection, supply the rational for further testing of Vigil in advanced stage Ewing's sarcoma.
Journal ArticleDOI
Potential use of RNA interference in cancer therapy
TL;DR: This review covers the rationale for pursuing personalised cancer therapy with RNAi, the mechanism of each major RNAi therapeutic technique, summarise and sample recent results with animal models applying RNAi for cancer, and provides an update on current clinical trials withRNAi-based therapeutic agents for cancer therapy.